Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05471011 · ClinicalTrials.gov registry record
COVID-19 Outcome Prediction Algorithm
A clinical trial of COVID-19 and Long COVID, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- 600
- Enrollment target
- 7
- Study locations
NCT05471011: Recruiting study of COVID-19 and Long COVID, sponsored by University of California, Los Angeles.
NCT05471011 is a study of COVID-19 and Long COVID that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 600 participants, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05471011, a study of COVID-19 and Long COVID, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 7
- Study locations
Study Summary
Severe acute respiratory syndrome coronavirus 2-mediated coronavirus disease (COVID-19) is an evolutionarily unprecedented natural experiment that causes major changes to the host immune system. We propose to develop a test that accurately predicts short- and long-term (within one-year) outcomes in hospitalized COVID-19 patients broadly reflecting US demographics who are at increased risk of adverse outcomes from COVID-19 using both clinical and molecular data. We will enroll patients from a hospitalized civilian population in one of the country's largest metropolitan areas and a representative National Veteran's population.
Primary Outcome
The primary outcome clinical composite endpoints that include new onset or worsening frailty, single organ dysfunction, multi organ dysfunction, and death within one year will include a follow-up period of time of at least 52 weeks after initial enrollment encounter. The assessment of time to event (outcome events will include various frailty measurement tools including short physical performance battery, laboratory test-based organ function assessment measures, and survival status as per public
Conditions Studied
Interventions
- OTHER Blood and nasal swab sampling
Study Locations (7)
California
- VA Greater Los Angeles Healthcare System - Los Angeles
- Ronald Reagan UCLA Medical Center - Los Angeles
- Olive View-UCLA Education & Research Institute - Sylmar
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - Torrance
Georgia
- Atlanta VA Medical Center - Decatur
New York
- Bronx VA Medical Center - The Bronx
Texas
- Michael E. DeBakey VA Medical Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2026-05-31 |
What NCT05471011 shows while recruiting
NCT05471011 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower).
The record links to 5 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Blood and nasal swab sampling is the first listed.
NCT05471011 lists 7 locations in 4 states (California, Georgia, New York).
Frequently Asked Questions
What is clinical trial NCT05471011 about?
NCT05471011 is a clinical study titled "COVID-19 Outcome Prediction Algorithm". Severe acute respiratory syndrome coronavirus 2-mediated coronavirus disease (COVID-19) is an evolutionarily unprecedented natural experiment that causes major changes to the host immune system. We propose to develop a test that accurately predicts short- and long-term (within one-year) outcomes in ...
What is the current status of trial NCT05471011?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2022-08-08. Estimated completion is 2026-05-31.
What conditions does trial NCT05471011 study?
This clinical trial studies the following conditions: COVID-19, Long COVID, Post Acute Sequelae of COVID-19, Frailty Syndrome, Organ Dysfunction Syndrome, Multiple.
What interventions are being tested in trial NCT05471011?
The interventions under investigation include: Blood and nasal swab sampling (OTHER).
Who is sponsoring clinical trial NCT05471011?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05471011 being conducted?
This trial has 7 study locations across California, Georgia, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05471011's enrollment target sits among peer trials
600 100th of 298 higher than 199 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI